

Paris and Toulouse, May 11, 2016

Limited company (société anonyme) with a Management Board (directoire)
and a Supervisory Board (conseil de surveillance)
with share capital of €1,555,566.60
Registered Office: Prologue-Biotech, 516 Rue Pierre et Marie Curie, 31670 Labège, France
Toulouse Trade and Companies Register (RCS) B 439 489 022

Disclosure of the total number of voting rights and shares composing the share capital

Persuant to Article 223-16 of the General Regulation of the French Financial Markets Authority
(AMF – Autorité des Marchés Financiers)

As of April 30th, 2016,

Total number of outstanding shares	15,555,666
Theoretical voting rights (1)	15,555,666
Shares without voting rights	
Treasury registered shares (2)	0
Treasury bearer shares (3)	20,087
Others (4)	0
Exercisable voting rights = (1) - [(2) + (3) + (4)]	15 535 579

About Genticel

Aiming to solve a public health issue.

Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001, its first-in-class immunotherapeutic candidate. GTL001 is more than halfway through a 24-month proof of concept Phase 2 trial in Europe.

Offering a promising technological platform.

Genticel's versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel's second candidate, GTL002, is a multivalent HPV immunotherapeutic candidate designed with Vaxiclase. It targets the six most relevant HPV types in terms of global epidemiology and is currently in preclinical development.

Focusing on value creation.

Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addition to this attractive HPV product pipeline, Genticel's versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SII), the world's largest producer of vaccine doses. This partnership could generate up to \$57 million in revenues for Genticel, before royalties on sales. It will enable SII to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.

For more information, visit us at www.genticel.com



Disclaimer

This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Gentigel shares in any country. This press release may contain forward-looking statements by the company with respect to its objectives. These statements are based on the current estimates and forecasts of the company's management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the [registration document](#), filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015 and those linked to changes in economic conditions, the financial markets, or the markets on which Gentigel is present. Gentigel products are currently used for clinical trials only and are not otherwise available for distribution or sale.

GENTIGEL	US INVESTORS	MEDIA
Valerie Leroy Investor Relations & Corporate Communications + 33 6 33 34 37 30 investors@gentigel.com	Life Sci Advisors Brian Ritchie +1 212 915 2578 britchie@lifesciadvisors.com	ALIZE RP Caroline Carmagnol et Florence Portejoie +33 6 64 18 99 59 / +33 6 47 38 90 04 gentigel@alizerp.fr